Transcranial direct current stimulation represents a cutting-edge approach in brain stimulation therapy, utilizing low-intensity electrical currents to modulate neuronal activity non-invasively. Characterized by its cost-effectiveness and safety profile, tDCS has demonstrated promising results in a variety of psychiatric and neurological disorders. Despite limited data, preliminary case reports involving fewer than ten patients have hinted at its potential efficacy in alleviating catatonia. To robustly explore this potential, the CATATOES study—a randomized, double-blind, placebo-controlled bicentric superiority trial—is set to rigorously evaluate the safety and efficacy of tDCS in patients exhibiting lorazepam-resistant catatonia.

The study is designed to enroll seventy individuals who have failed to respond to lorazepam, reflecting an urgent need for alternative interventions. Participants will undergo a comprehensive treatment regimen involving twenty sessions of tDCS, administered twice daily. Each session delivers a current of two milliamperes for twenty minutes, with precise electrode placement that targets specific brain regions implicated in catatonia’s neuropathophysiology. The anode will be positioned over the left dorsolateral prefrontal cortex (DLPFC), a region involved in executive function and motor planning, while the cathode will be placed over the left temporoparietal junction (TPJ), associated with sensory integration and social cognition.

The study’s methodological rigor extends beyond clinical assessments. Multimodal neuroimaging—including structural, functional, and diffusion magnetic resonance imaging (MRI)—will be employed serially to elucidate the neural circuits influenced by tDCS. Complementing imaging, high-density 64-channel electroencephalography (EEG) recordings at rest will provide rich electrophysiological data, potentially revealing biomarkers of treatment response and mechanistic insights. Furthermore, comprehensive blood analyses will track inflammatory markers, neurogenesis-related factors, and genetic variables, offering a molecular dimension to this multifaceted investigation.

Catatonia’s pathophysiology remains incompletely understood, but mounting evidence implicates disruptions in cortico-subcortical circuits and neurotransmitter systems. By focusing stimulation on the DLPFC and TPJ, the CATATOES study targets nodes within these dysfunctional networks, hypothesizing that tDCS may restore cortical excitability and connectivity balance. This hypothesis aligns with broader neuroscientific concepts positing that modulating dysfunctional neural dynamics can ameliorate complex brain disorders. Should tDCS prove efficacious, it would represent a paradigm shift, introducing an accessible, minimally invasive treatment option for refractory catatonia.

The implications of this research extend well beyond symptom remission. Catatonia is associated with significant healthcare burdens, including prolonged hospital stays, increased mortality, and high treatment costs. Conventional options like ECT, while effective, carry risks and face barriers related to stigma, availability, and patient tolerance. Successful demonstration of tDCS as a reliable therapeutic tool could democratize access to care, reduce healthcare costs, and importantly, improve quality of life for a vulnerable patient population. The CATATOES study thereby holds promise for transforming the therapeutic landscape in psychiatry.

In conducting this study across two clinical centers, the research team ensures a sufficiently diverse patient cohort, which enhances the generalizability and robustness of findings. Blinded administration and placebo control safeguard against bias, a critical aspect for maintaining scientific rigor in clinical trials involving subjective and potentially fluctuating neuropsychiatric symptoms. By employing rigorous randomization and double-blind protocols, the study aims to definitively ascertain whether tDCS can outperform sham stimulation in ameliorating catatonia.

Beyond therapeutic outcomes, accompanying mechanistic investigations offer a rare opportunity to deepen understanding of catatonia itself. Combining neuroimaging, electrophysiology, and molecular biology, the study endeavors to unravel fundamental pathophysiological processes. Such insights could pave the way for biomarker development and personalized treatment strategies, advancing precision psychiatry. A more nuanced comprehension of how neural circuits and biochemical pathways interact in catatonia could also inspire targeted interventions for related neuropsychiatric disorders.

The CATATOES trial is registered at ClinicalTrials.gov with the identifier NCT06139432 and commenced recruitment in late 2023. Enrolment and data collection are expected to proceed over the coming years, with outcomes anticipated to contribute substantially to the evidence base for tDCS in neuropsychiatry. The combined expertise of psychiatrists, neuroscientists, and clinical trialists underscores the multidisciplinary nature of this effort, reflecting contemporary approaches to complex brain disorders.

In sum, the CATATOES study represents a bold, methodologically sophisticated foray into employing non-invasive brain stimulation to revolutionize catatonia treatment. By harnessing the neuromodulatory capacity of tDCS, this research has the potential to overcome longstanding challenges posed by lorazepam-resistant cases. Success in this endeavor could ultimately translate into reduced mortality, enhanced patient recovery, and diminished healthcare burden—objectives that resonate profoundly within psychiatry and neurology communities worldwide.

As scientific understanding and technological innovation converge, the mental health field stands on the brink of transformative therapies. The CATATOES trial exemplifies how rigorously designed clinical research can translate emerging neuroscientific insights into practical treatment advances. This study not only addresses an urgent clinical need but also emboldens future translational work aimed at decoding and treating brain disorders with precision, compassion, and innovation.

Subject of Research: Lorazepam-resistant catatonia and efficacy of transcranial direct current stimulation (tDCS) as an alternative therapeutic intervention.

Article Title: CATATOnia treatment with transcranial direct current electrostimulation: protocol of a randomised, double-blind, placebo-controlled bicentric superiority study (CATATOES).

Article References: Moyal, M., Attali, D., Berre, A.L. et al. CATATOnia treatment with transcranial direct current electrostimulation: protocol of a randomised, double-blind, placebo-controlled bicentric superiority study (CATATOES). BMC Psychiatry 25, 949 (2025). https://doi.org/10.1186/s12888-025-07266-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07266-5

Catatonia is a multifaceted and severe motor and behavioral syndrome characterized by symptoms ranging from stupor and mutism to agitation and rigidity. For decades, catatonia was primarily understood within the context of schizophrenia spectrum disorders, often perceived narrowly as a subtype of these illnesses. However, contemporary diagnostic frameworks like the DSM-5-TR and ICD-11 have redefined catatonia as a specifier rather than a standalone diagnosis, acknowledging its presence across a broad spectrum of psychiatric and medical conditions. This expanded clinical understanding necessitates diversified treatment approaches that can be adapted to varied care environments.

Electroconvulsive therapy remains the gold standard treatment for catatonia, particularly for malignant forms that pose immediate health risks. Despite its therapeutic effectiveness, ECT is often unavailable in many psychiatric facilities worldwide or contraindicated in patients with certain medical comorbidities or frailty, thus leaving clinicians in a therapeutic quandary. Benzodiazepines, another frontline treatment, can be effective but are sometimes insufficient or cause undesirable side effects. This context underscores the urgent need for alternative or adjunctive pharmacological modalities that are both safe and accessible.

The research team reported on five distinct cases of catatonia, including malignant presentations, treated within psychiatric hospital and outpatient settings in Japan that lacked ECT capabilities. These cases all involved patients diagnosed with schizophrenia or schizoaffective disorder. Clinical intervention centered on administering extended-release guanfacine in conjunction with short-term benzodiazepine therapy. This combination yielded complete syndromal remission from catatonic symptoms in all five patients, an outcome that is both remarkable given the treatment context and highly encouraging for future therapeutic strategies.

Guanfacine’s pharmacological action is rooted in its selective agonism of central α2A adrenoceptors, which modulates norepinephrine release within the central nervous system. This action is mechanistically related to dexmedetomidine, a sedative known for its efficacy in managing catatonia but primarily used in critical care due to its intravenous administration. Guanfacine’s oral availability and relatively favorable side effect profile provide a significant clinical advantage, allowing for broader outpatient use without the logistical complications associated with sedative infusions.

The study also sheds light on the potential underlying pathophysiology of catatonia, implicating central noradrenergic dysfunction as a contributing factor. The alleviation of symptoms through α2A adrenoceptor modulation by guanfacine supports the hypothesis that abnormal norepinephrine signaling may play a crucial role in catatonic presentations. This insight broadens the scientific understanding of catatonia beyond the dopaminergic and GABAergic systems historically emphasized in neuropsychiatric research.

While the therapeutic outcomes were overwhelmingly positive, the authors detail mild to moderate side effects experienced by some patients, including dizziness, fatigue, hypotension, and bradycardia. Notably, these adverse effects were manageable through dose adjustments, suggesting that guanfacine’s safety profile is acceptable with careful clinical monitoring. This mitigates concerns about introducing a new pharmacotherapy in populations already vulnerable to complex medical issues.

The report also discusses the clinical complications associated with catatonia, which ranged from impaired oral intake requiring nutritional intervention to the need for urinary catheterization due to immobility. The management of these complications alongside pharmacological treatment underscores the importance of a multidisciplinary approach when addressing catatonia, emphasizing the role of supportive care in tandem with novel pharmacotherapies like guanfacine.

This case series not only provides valuable clinical evidence but also identifies a significant gap in current psychiatric practice—the limited treatment options for catatonia in settings without ECT availability. The ability to achieve remission through guanfacine administration presents a promising alternative pathway that could enhance patient outcomes globally, especially in resource-limited contexts.

The researchers advocate for further investigations to validate these preliminary findings through larger-scale studies and randomized controlled trials. Such research will be essential to establish standardized dosing regimens, assess long-term safety, and elucidate the precise neurobiological mechanisms by which guanfacine exerts its effects on catatonic symptoms. This could pave the way for guanfacine’s integration into catatonia treatment guidelines.

Ultimately, the successful treatment of catatonia with guanfacine as documented in this series holds significant implications for neuropsychiatry. It reflects a move towards targeted pharmacological modulation of neurochemical systems implicated in psychomotor and behavioral disorders. By expanding the armamentarium for catatonia management, clinicians may offer hope to patients who previously had limited therapeutic options due to the constraints related to ECT and benzodiazepine therapy.

Given the complexities and dangers posed by malignant catatonia, the emergence of guanfacine as a potentially viable treatment alternative is a beacon of hope. Its use could reduce reliance on invasive procedures and broaden the scope of inpatient and outpatient care for severe neuropsychiatric disorders. As such, this research deserves widespread attention within the psychiatric and neuroscience communities, heralding a new chapter in catatonia treatment.

In conclusion, the pioneering work published by Saito, Tiger, Arakawa, and colleagues challenges existing treatment paradigms and enriches the scientific dialogue about catatonia’s pathophysiology and management. Guanfacine’s role as an α2A adrenoceptor agonist offers an innovative therapeutic mechanism that has now been empirically supported in humans with promising clinical outcomes. The medical community eagerly awaits further studies that will confirm and build upon these initial successes.

Subject of Research: Catatonia treatment with guanfacine as an alternative to electroconvulsive therapy in patients with schizophrenia spectrum disorders.

Article Title: Successful treatment of five cases of catatonia treated with guanfacine without ECT: a case series from a psychiatric hospital in Japan.

Article References:
Saito, H., Tiger, M., Arakawa, R. et al. Successful treatment of five cases of catatonia treated with guanfacine without ECT: a case series from a psychiatric hospital in Japan. BMC Psychiatry 25, 903 (2025). https://doi.org/10.1186/s12888-025-07349-3

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07349-3